Neuronal Stem Cell Transplantation For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neuronal stem cell transplantation represents a promising therapeutic approach for neurodegenerative diseases, aiming to replace lost neurons, provide neurotrophic support, modulate inflammation, and restore neural circuits. Multiple stem cell types are being investigated, each with distinct advantages and limitations.
- Source: Inner cell mass of blastocysts
- Potential: Can differentiate into all neuronal subtypes
- Concerns: Ethical issues, tumor formation risk, immune rejection
- Source: Patient-derived reprogrammed cells
- Potential: Autologous transplantation possible, disease modeling
- Concerns: Genetic instability, reprogramming artifacts, cost
- Source: Fetal brain tissue or ESC/iPSC differentiation
- Potential: Lineage-restricted, lower tumor risk
- Concerns: Limited expansion, immune rejection
- Source: Bone marrow, adipose tissue, umbilical cord
- Potential: Immunomodulatory, neurotrophic support
- Concerns: Limited neuronal differentiation
- Source: Direct reprogramming of fibroblasts
- Potential: Patient-specific neurons, no pluripotency
- Concerns: Immaturity, integration
- Direct substitution of lost neurons
- Integration into existing neural circuits
- Formation of appropriate synaptic connections
- Secretion of BDNF, GDNF, NGF
- Support of endogenous neuron survival
- Promotion of axonal regeneration
- Reduction of pro-inflammatory cytokines
- Promotion of anti-inflammatory phenotypes
- Protection of endogenous neurons
- Exosome-mediated effects
- Metabolic support
- Angiogenesis promotion
- Target: Dopaminergic neurons in substantia nigra
- Cell types: ESC-derived DA neurons, iPSC-derived DA neurons
- Trials: Multiple Phase I/II trials ongoing
- Status: Promising but challenging
- Target: Medium spiny neurons in striatum
- Cell types: ESC-derived GABAergic neurons
- Trials: Phase I trials completed
- Status: Early stage
- Target: Motor neurons in spinal cord
- Cell types: NSC transplantation, MSC therapy
- Trials: Multiple Phase I/II trials
- Status: Safety established, efficacy unclear
- Target: Hippocampal neurons, cholinergic neurons
- Cell types: NSCs, ESC-derived cholinergic neurons
- Trials: Early-stage investigations
- Status: Preclinical/early clinical
¶ Stroke and Spinal Cord Injury
- Target: Damaged neural tissue
- Cell types: NSCs, MSCs
- Trials: Multiple trials ongoing
- Status: Some functional improvements
- Disease modification: Potential to halt or reverse progression
- Personalized medicine: Patient-specific iPSC lines
- Combination potential: With gene therapy or small molecules
- Cell survival: Low survival rates after transplantation
- Integration: Proper circuit integration is difficult
- Immune rejection: Requires immunosuppression
- Tumor risk: Especially with pluripotent stem cells
- Delivery: Surgical implantation required
- Cost: Extremely expensive
- Teratoma formation: Risk with pluripotent cells
- Overgrowth: Uncontrolled cell proliferation
- Dyskinesias: Particularly in PD (from excess dopamine)
- Seizures: Possible with certain transplants
- 3D organoids: Brain organoids for transplantation
- Gene-edited cells: CRISPR-corrected patient cells
- Combined therapies: Stem cells + gene therapy
- Biomaterial scaffolds: Support cell survival and integration
- In vivo reprogramming: Direct conversion in the brain
The study of Neuronal Stem Cell Transplantation For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lindvall O, et al. (2012). "Transplantation of mesenchvmal stem cells to enhance regeneration." Cell Stem Cell. PMID:22704471
- Kriks S, et al. (2011). "Dopamine neurons derived from ESCs." Nature. PMID:21617634
- Takahashi J. (2020). "iPSC-based Parkinson's disease modeling." NPJ Parkinson's Disease. PMID:32047854
- Cunningham M, et al. (2015). "Neural stem cell therapy for stroke." Annals of Neurology. PMID:25933563
- Glass JD, et al. (2020). "Cell therapy for ALS." Annals of Neurology. PMID:32880936